How Much Does a PSMA PET CT Scan Cost?

MIC uses PET CT imaging in several applications: heart (cardiac) imaging, cancer (oncology) imaging, and brain (neurology) imaging. Currently, the Alberta Health Care Insurance Plan (AHCIP) only covers the cost of PET CT imaging in cardiac applications when performed in a community-based clinic outside the hospital.

While Health Canada approved the first PSMA radiopharmaceutical in October 2022, routine use of PSMA-PET has not been established in Canada, and access is mainly through clinical trials, private healthcare, and registries.

The cost of a PSMA PET CT for a cancer application at MIC depends on whether an accompanying diagnostic CT is acquired simultaneously. Our team will happily speak to you to tailor an exam to your needs.

  • PSMA PET CT (diagnostic CT included) is $TBD
  • PSMA PET (diagnostic CT excluded) is $TBD

Patients are encouraged to talk to their employer or a Benefits Specialist before booking their exam to see if they qualify for extended coverage. Some extended benefits programs or health spending accounts may cover a portion or possibly the entire exam fee.



At MIC, we use a Health Canada-approved radiotracer, 68-Gallium PSMA-11. Other commonly used radiotracers available through clinical trials are 18F PSMA compounds.
No. Although there is a high expression of this protein on prostate tissue and prostate cancer cells, the protein can be found in low amounts in other organ tissues. The uptake pattern plays an important role in interpreting your PSMA PET CT exam.
Although there is no diagnostic imaging test that can provide 100% confirmation of metastatic cancer, PSMA PET CT appears to be the most sensitive and accurate test currently available for identifying metastatic sites of disease in prostate cancer.
Patients must not eat or drink anything except plain water for a minimum of 4 hours before the appointment.

Patient preparation instructions vary depending on the type of PET CT exam performed. Our booking team will provide detailed instructions when you schedule your exam. It is important to follow the preparation instructions closely, as improper preparation can affect the scan's results or cause the scan to be rescheduled.

If you have any questions or concerns about your preparation, our booking team is happy to help. When you schedule your appointment, our team will review specific exam preparation instructions based on your PET CT study.
No. You should be able to continue your normal medications with unchanged doses.
Theranostics (therapeutics + diagnostics = theranostics) is a two-pronged approach to diagnosing and treating cancers through the use of radiotracers.

PSMA is an example of a theranostic agent. If the radioactive component is switched to a therapeutic one (i.e. 68Ga/18F is switched to 177Lu/225Ac), it can specifically target and treat the cancer cells. Before a therapeutic radiotracer is used, patients generally must have a diagnostic scan first, to confirm and assess the ability to target the tumor cells.
Occasionally, to help with treatment decision-making, your physician may request both PSMA and FDG PET CT scans to help characterize the tumours or metastases. The PSMA PET scan shows how many tumour cells still have the PSMA receptors, while the FDG PET scan shows how metabolically active the cells are.

Each of these PET scans provides complementary information to aid the clinician in making the optimal personalized treatment decision for each individual.
Alberta Cancer Foundation. (2024). Better Prostate Cancer Outcomes with the PSMA PET.
Government of Canada. (2021, March). Prostate cancer in Canada.
Government of Canada Drug and Health Product Portal. (2024). Regulatory Decision Summary for Illuccix.®
My Leap Magazine. (2023). New Technology: Taking Prostate Cancer Imaging to the Next Level.,received%20a%20PSMA%2DPET%20scan
Society of Nuclear Medicine and Molecular Imaging. (2021). Prostate-Specific Membrane Antigen (PSMA) PET Scan.
Telix Pharmaceuticals Limited. (2022, October). Health Canada Approves Illuccix® for Prostate Cancer Imaging.